Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.202,17
0,48%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Xeris Biopharma Holdings Inc (XERS) Xeris Biopharma Holdings Inc (XERS) Notizie

Xeris Biopharma Holdings Inc

XERS
1,93
0,07 (3,76%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/5/202413:00BWXeris Biopharma to Report First Quarter 2024 Financial..
03/4/202422:05BWXeris Pharmaceuticals Announces Inducement Grants Under..
02/4/202413:00BWXeris Biopharma to Participate in the 23rd Annual Needham..
06/3/202422:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/3/202422:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202413:27EDGAR2Form 8-K - Current report
06/3/202413:02BWXeris Biopharma Reports Fourth Quarter and Full Year 2023..
06/3/202413:00BWXeris Refinances Its $150M Senior Secured Term Loan Facility..
28/2/202413:00BWXeris Biopharma to Report Fourth Quarter and Full Year 2023..
05/2/202413:00BWXeris to Present at the Oppenheimer 34th Annual Healthcare..
31/1/202423:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202416:12DJNXeris Biopharma Shares Climb 12% on Amgen License Agreement
10/1/202414:53DJNXeris Biopharma Reaches License Agreement With Amgen On..
10/1/202414:00BWXeris Biopharma Enters Into an Exclusive Worldwide License..
05/1/202422:05BWXeris Pharmaceuticals Announces Inducement Grants Under..
04/1/202413:09EDGAR2Form 8-K - Current report
04/1/202413:00BWXeris Biopharma Updates Its Outlook for 2023
27/12/202313:00BWXeris Biopharma to Present at the 42nd Annual J.P. Morgan..
21/11/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:20EDGAR2Form 8-K - Current report
09/11/202313:00BWXeris Biopharma Reports Third Quarter 2023 Financial Results
16/10/202313:12EDGAR2Form 8-K - Current report
16/10/202313:00BWXeris Biopharma Raises Full-Year Financial Guidance and..
29/9/202322:55EDGAR2Form 8-K - Current report
27/9/202314:11EDGAR2Form 8-K - Current report
27/9/202314:00BWXeris Biopharma Announces Private Convertible Note Exchange..
14/9/202322:05BWXeris to Participate in the 2023 Cantor Global Healthcare..
28/8/202313:00BWXeris to Participate at the H.C. Wainwright 25th Annual..
08/8/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:23EDGAR2Form 8-K - Current report
08/8/202313:00BWXeris Biopharma Reports Second Quarter 2023 Financial..
01/8/202313:00BWXeris Biopharma to Report Second Quarter 2023 Financial..
31/7/202313:00BWXeris Ships One Millionth Gvoke® Unit
28/6/202322:28EDGAR2Form 8-K - Current report
21/6/202313:00BWXeris Biopharma Announces First Participant Dosed in a Phase..
01/6/202313:00BWXeris Biopharma to Participate at the Jefferies Healthcare..
09/5/202313:00BWXeris Biopharma Reports First Quarter 2023 Financial Results
Apertura: 1,90 Min: 1,84 Max: 1,93
Chiusura: 1,86

La tua Cronologia

NASDAQ
XERS
Xeris Biopharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network